business
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications - investor.lilly.com
Triumph-1 Study Results: Significant Weight Loss and Improved Health Outcomes with Retrutide The Triumph-1 study is a groundbreaking clinical trial that has achieved remarkable results in weight loss and improved health outcomes for participants treated with retetrutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The study&